Home > Academic Announcements > (Dec. 14) Frontiers in Medical Sciences Lecture 316-Cancer Immunotherapy by Trifunctional Bispecific Antibodies

(Dec. 14) Frontiers in Medical Sciences Lecture 316-Cancer Immunotherapy by Trifunctional Bispecific Antibodies

Last updated :2017-12-11

Topic: Cancer Immunotherapy by Trifunctional Bispecific Antibodies
Speaker: Dr. Xiao Shen
(Guangzhou Han Teng Biological Technology Co., Ltd.)
Host: Professor Guangmei Yan (Zhongshan School of Medicine, SYSU)
Time: 10:30 am, Thursday, December 14, 2017
Venue: 946, 7th Floor, Science and Technology Building, Guangzhou North Campus, SYSU

About the speaker:
Xiao Shen, PhD from Swiss federal polytechnic university, founder and chairman of Guangzhou Han Teng Biotechnology Co., Ltd. and Guangzhou Ling Teng Biomedical Co., Ltd. He won the Guangdong Province "Pearl River Talents Program," the introduction of innovation and entrepreneurship team leader, the first session of the Guangzhou Development Zone entrepreneurial excellence and so on. And he was appointed as the Overseas Chinese Federation of Overseas Chinese Innovation and Entrepreneurship Alliance, Sun Yat-sen University College of Pharmacy student entrepreneurship mentor, South China Agricultural University student entrepreneurship mentor. Dr. Xiao Shen successively worked in the field of biomedical engineering in such famous universities and research institutes as Sun Yat-sen University, Heidelberg University in Germany, German Oncology Center and Swiss Federal Institute of Technology Lausanne. His Ph.D. tutor was Prof. Florian Wurm, a biopharmaceutical specialist, he has been engaged in large-scale animal cell culture and recombinant protein drug production technology research. During this period, he has spoken at major academic conferences and assisted in the development and production of new drugs by multinational pharmaceutical companies Process development work. After returning to China, he founded Guangzhou Han Teng Biotechnology Co., Ltd. and Foshan Han Teng Biotechnology Co., Ltd. to provide biopharmaceutical CDMO development for pharmaceutical companies, biotechnology companies and research institutes. Later, he founded Lingtung Biomedical Active Company with Dr. Horst Lindhofer, the inventor of the world's first bispecific antibody. Combining the strengths of both parties in the field of drug development and CMC, the company developed the next generation anti-tumor immunotherapy double antibody and developed double-specific antibody standards.